This is the authors' abstract. We don't add key points for this paper.
Backgound Induction of fetal hemoglobin (HbF; α2γ2) production can alleviate the clinical severity of sickle cell disease (SCD) and β-thalassemia. KLF1 SNPs (e.g. rs2072597) correlate with elevated fetal hemoglobin levels in HPFH patients. Some studies suggest that KLF1 may indirectly suppress γ-globin expression by regulating the KLF1-dependent transcriptional repressor BCL11A or directly activate γ-globin. This study aims to investigate the effect of KLF1 on the γ-globin gene.Material/Methods KLF1 was downregulated in K562 cells via RNAi, with optimized shRNA delivered by lentivirus. Additionally, an in vitro erythropoiesis model using β-thalassemia major-derived mononuclear cells (MNCs) assessed γ-globin expression. γ-globin levels were quantified by RT-qPCR and Western blot (K562) or RT-qPCR alone (erythroblasts).Results Knockdown of KLF1 in K562 cells significantly suppressed γ-globin expression and elevated the γ/α globin mRNA ratio in human erythrocytes, concurrent with disrupted erythroid maturation. KLF2 expression was upregulated under KLF1-deficient conditions.Conclusions KLF1 exhibits dual, context-dependent regulation of globin genes, acting as both activator and repressor. These findings suggest that pharmacological targeting of KLF1 may not be an optimal therapeutic strategy for β-hemoglobinopathies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: